Drug Testing Supplies for Opioid Treatment Programs

42 CFR 8.12(f)(6) requires every federally-certified OTP to conduct at least eight random drug tests per patient per year, with results documented in the patient record. The 2024 rule update preserved the eight-test minimum while giving programs additional flexibility on the specific schedule and panel composition based on clinical judgment. The minimum is a floor — many programs test more frequently for patients early in treatment or after aberrant results, with the frequency tapering as the patient stabilizes.

For most OTPs, yes. Fentanyl does not cross-react with the standard morphine-based opiate immunoassay, so a patient using fentanyl can test negative on a 12-panel that doesn't include fentanyl as a dedicated analyte. Given fentanyl's role in current overdose mortality, most OTPs have moved to 13- or 14-panel cups that include fentanyl on the same cup. Programs in regions with significant xylazine adulteration may also use harm-reduction xylazine strips alongside the standard cup.

The CLIA-waived cup result is a screening result that is clinically useful for ongoing monitoring and supports the medical director's documented take-home assessment. For any individual aberrant result that will significantly affect treatment — such as suspending take-homes that have already been granted, or denying take-homes that would otherwise be granted — many programs lab-confirm the aberrant result before acting. Document the rationale and the confirmation result in the patient record.

The 2024 SAMHSA rule revision substantially loosened the time-in-treatment criteria that previously governed take-home medication and gave OTP medical directors more clinical-judgment authority. Programs can grant take-homes earlier in treatment for patients judged stable, with the medical director's documented assessment — typically including recent drug-testing history showing absence of illicit drug use — as the central justification. This makes the drug-testing documentation more clinically important, not less, even as the calendar-based criteria have loosened.

42 CFR Part 8 does not require all OTP random tests to be observed, but program policies typically require observed collection in defined circumstances: after an aberrant result, at the start of treatment, when there is reason to believe the patient may attempt to alter the specimen, or per state opioid treatment authority requirements. Most programs use unobserved collection as the default with documented criteria for moving to observed collection. Specimen-validity testing (creatinine, pH, oxidants) on the cup provides a check on unobserved collections.

42 CFR Part 2 — the federal confidentiality regulation for SUD treatment records — is stricter than HIPAA and applies to all OTP drug-testing results. Results cannot be released to courts, drug courts, employers, family members, or even other healthcare providers without specific written consent meeting Part 2's requirements, or one of the narrow exceptions (medical emergency, properly-issued court order that specifically addresses Part 2 records). The 2024 Part 2 rule update aligned some areas with HIPAA but retained the core consent requirement.

There is no minimum to open a wholesale account. Tiered pricing kicks in at 100 units of a SKU and scales meaningfully at 500 and 1,000+. A typical 200-patient OTP runs the minimum 8 random tests per patient per year (1,600 cups) plus admission, take-home, and clinically-indicated tests — most qualify for the second or third tier on first order. A 500-patient program ordering 4,000+ cups per year qualifies for the highest tier.

Yes — our partner lab network supplies chain-of-custody forms, HHS-certified laboratory confirmation by GC-MS or LC-MS-MS, and MRO services. For any result that may end up in a drug court report, custody proceeding, or other legal context, we recommend documented forensic chain of custody — the SAMHSA Federal CCF is one widely-used option; many programs use a court-aligned form preferred by their local drug court. Programs with existing lab relationships buy kits-only at the same wholesale pricing.